Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents Insights From the Xience V Coronary Stent System Trials

被引:53
作者
Genereux, Philippe [1 ,2 ,3 ]
Rutledge, David R. [4 ]
Palmerini, Tullio [5 ]
Caixeta, Adriano [6 ,7 ]
Kedhi, Elvin [8 ]
Hermiller, James B. [9 ]
Wang, Jin [4 ]
Krucoff, Mitchell W. [10 ]
Jones-McMeans, Jennifer [4 ]
Sudhir, Krishnankutty [4 ]
Simonton, Charles A. [4 ]
Serruys, Patrick W. [11 ]
Stone, Gregg W. [1 ,2 ]
机构
[1] Columbia Univ, Med Ctr, New York, NY 10022 USA
[2] Cardiovasc Res Fdn, New York, NY USA
[3] Univ Montreal, Hop Sacre Coeur Montreal, Montreal, PQ, Canada
[4] Abbott Vasc, Santa Clara, CA USA
[5] Univ Bologna, Ist Cardiol, I-40126 Bologna, Italy
[6] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil
[7] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[8] Isala Klin, Zwolle, Netherlands
[9] St Vincent Heart Ctr Indiana, Indianapolis, IN USA
[10] Duke Univ, Med Ctr, Durham, NC USA
[11] Erasmus Univ Hosp, Rotterdam, Netherlands
关键词
drug-eluting stents; stents; thrombosis; LONG-TERM DURATION; MYOCARDIAL-INFARCTION; SPIRIT II; PREDICTORS; METAANALYSIS; DISCONTINUATION; IMPLANTATION; CLOPIDOGREL; EFFICACY; IMPACT;
D O I
10.1161/CIRCINTERVENTIONS.114.001362
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Whether premature dual antiplatelet therapy (DAPT) interruption is safe in patients receiving cobalt chromium everolimus-eluting stents remains controversial. We sought to examine the relationship between DAPT discontinuation and stent thrombosis (ST) after cobalt chromium everolimus-eluting stents. Methods and Results-Outcomes from 11 219 patients were pooled from 3 randomized trials and 4 registries with 2-year follow-up period after cobalt chromium everolimus-eluting stent implantation. Rates of definite/probable ST were analyzed according to DAPT discontinuation in the following time intervals: 0 to 30, 30 to 90, 90 to 180, 180 to 365, and 365 to 730 days. Eighty-five cases of ST (0.75%) occurred in 83 patients during 2 years, with 41 (48.2%) events occurring within 30 days. The 2-year ST rate in patients interrupting DAPT at any time was similar to that in patients never interrupting DAPT through 2 years (25/4067 [0.63%] versus 58/7152 [0.83%] respectively; P=0.27]. By propensity and DAPT usage-adjusted multivariable analysis, permanent DAPT discontinuation before 30 days was independently associated with the occurrence of ST (hazard ratio [95% confidence interval], 26.8 [8.4-85.4]; P<0.0001), whereas permanent DAPT discontinuation in any interval after 90 days was not associated with ST. Only 2 ST events occurred after DAPT discontinuation between 30 and 90 days (both between 30 and 60 days), and the association between permanent DAPT discontinuation and ST during this period is unclear (hazard ratio [95% confidence interval], 8.7 [2.0-37.3]; P=0.004 for adjusted analysis and 3.4 [0.8-13.8]; P=0.07 for the unadjusted analysis). Conclusions-In this large pooled experience, permanent DAPT discontinuation before 30 days after cobalt chromium everolimus-eluting stent implantation was strongly associated with ST, whereas DAPT discontinuation beyond 90 days appeared safe.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] XIENCE V™ Everolimus-Eluting Coronary Stent System: A Preclinical Assessment
    Perkins, Laura E. L.
    Boeke-Purkis, Katrin H.
    Wang, Qing
    Stringer, Steven K.
    Coleman, Leslie A.
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2009, 22 : S28 - S40
  • [2] Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes Pooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials
    Planer, David
    Smits, Pieter C.
    Kereiakes, Dean J.
    Kedhi, Elvin
    Fahy, Martin
    Xu, Ke
    Serruys, Patrick W.
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (10) : 1104 - 1115
  • [3] Evaluation of an Everolimus-Eluting Dedicated Bifurcation Stent in Comparison with Xience V™ Coronary Stent in a Porcine Coronary Model
    Sorop, Oana
    van Beusekom, Heleen M.
    Krabbendam, Ilona
    Boeke-Purkis, Katrin
    van der Giessen, Willem J.
    CIRCULATION, 2010, 122 (21)
  • [4] Clinical Impact of Dual Antiplatelet Therapy Use in Patients Following Everolimus-eluting Stent Implantation: Insights from the SEEDS Study
    Zhang, Yao-Jun
    Zhao, Ye-Lin
    Xu, Bo
    Han, Ya-Ling
    Li, Bao
    Liu, Qiang
    Su, Xi
    Pang, Si
    Lu, Shu-Zheng
    Guo, Xiao-Feng
    Yang, Yue-Jin
    CHINESE MEDICAL JOURNAL, 2015, 128 (06) : 714 - 720
  • [5] Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
    Kereiakes, Dean J.
    Sudhir, Krishnankutty
    Hermiller, James B.
    Gordon, Paul C.
    Ferguson, Joanne
    Yaqub, Manejeh
    Sood, Poornima
    Su, Xiaolu
    Yakubov, Steven
    Lansky, Alexandra J.
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (12) : 1229 - 1239
  • [6] Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials
    Tanimoto, Shuzou
    Serruys, Patrick W.
    Thuesen, Leif
    Dudek, Dariusz
    de Bruyne, Bernard
    Chevalier, Bernard
    Ormiston, John A.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 70 (04) : 515 - 523
  • [7] Stent Thrombosis With Everolimus-Eluting Stents Meta-Analysis of Comparative Randomized Controlled Trials
    Palmerini, Tullio
    Kirtane, Ajay J.
    Serruys, Patrick W.
    Smits, Pieter C.
    Kedhi, Elvin
    Kereiakes, Dean
    Sangiorgi, Diego
    Reggiani, Letizia Bacchi
    Kaiser, Christoph
    Kim, Hyo-Soo
    De Waha, Antoinette
    Ribichini, Flavio
    Stone, Gregg W.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (03) : 357 - 364
  • [8] Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial
    Stone, Gregg W.
    Midei, Mark
    Newman, William
    Sanz, Mark
    Hermiller, James B.
    Williams, Jerome
    Farhat, Naim
    Caputo, Ronald
    Xenopoulos, Nicholas
    Applegate, Robert
    Gordon, Paul
    White, Roseann M.
    Sudhir, Krishnankutty
    Cutlip, Donald E.
    Petersen, John L.
    CIRCULATION, 2009, 119 (05) : 680 - 686
  • [9] Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents
    Hermiller, James B.
    Krucoff, Mitchell W.
    Kereiakes, Dean J.
    Windecker, Stephan
    Steg, P. Gabriel
    Yeh, Robert W.
    Cohen, David J.
    Cutlip, Donald E.
    Massaro, Joseph M.
    Hsieh, Wen-Hua
    Mauri, Laura
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (02) : 138 - 147
  • [10] Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan
    Aoki, Jiro
    Kozuma, Ken
    Awata, Masaki
    Nanasato, Mamoru
    Shiode, Nobuo
    Tanabe, Kengo
    Yamaguchi, Junichi
    Kusano, Hajime
    Nie, Hong
    Kimura, Takeshi
    CIRCULATION JOURNAL, 2016, 80 (04) : 906 - +